Review

proteinchip data manager biomarker wizard (Bio-Rad)

Bio-Rad is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bio-Rad proteinchip data manager biomarker wizard

Longitudinal PiB SUVR data from the IMAGINE double-blind phase. Line graphs showing the mean (±SEM) PiB SUVR at baseline and at 12 months for the placebo (blue circles) and PBT2 (red circles) groups. As a contemporaneous control group, a group of 46 AIBL participants (black circles) meeting the IMAGINE inclusion criteria and matched for IMAGINE baseline PiB SUVR. While there were no significant differences between placebo and PBT2 at 12 months, there was a significant decrease of 0.09 PiB SUVR/yr in the PBT2 group ( P = .048). While the IMAGINE placebo group showed a nonsignificant decrease of 0.08 PiB SUVR/yr, the AIBL participants showed a significant increase of 0.04 PiB SUVR/yr ( P = .0014), and an even greater increase (0.07 PiB SUVR/yr) was observed in the APOE ε4 placebo group of the bapineuzumab trial . Abbreviations: AIBL, Australian Imaging <t>Biomarker</t> and Lifestyle Study; SUVR, standardized uptake volume ratio. ∗∗ P < .001.

Proteinchip Data Manager Biomarker Wizard, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 85 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteinchip data manager biomarker wizard/product/Bio-Rad
Average 93 stars, based on 85 article reviews

proteinchip data manager biomarker wizard - by Bioz Stars, 2026-04

93/100 stars

Images

1) Product Images from "A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study"

Article Title: A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study

Journal: Alzheimer's & Dementia : Translational Research & Clinical Interventions

doi: 10.1016/j.trci.2017.10.001

Figure Legend Snippet: Longitudinal PiB SUVR data from the IMAGINE double-blind phase. Line graphs showing the mean (±SEM) PiB SUVR at baseline and at 12 months for the placebo (blue circles) and PBT2 (red circles) groups. As a contemporaneous control group, a group of 46 AIBL participants (black circles) meeting the IMAGINE inclusion criteria and matched for IMAGINE baseline PiB SUVR. While there were no significant differences between placebo and PBT2 at 12 months, there was a significant decrease of 0.09 PiB SUVR/yr in the PBT2 group ( P = .048). While the IMAGINE placebo group showed a nonsignificant decrease of 0.08 PiB SUVR/yr, the AIBL participants showed a significant increase of 0.04 PiB SUVR/yr ( P = .0014), and an even greater increase (0.07 PiB SUVR/yr) was observed in the APOE ε4 placebo group of the bapineuzumab trial . Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; SUVR, standardized uptake volume ratio. ∗∗ P < .001.

Techniques Used: Control, Imaging, Biomarker Discovery

Longitudinal PiB SUVR data from participants who completed the two phases of the IMAGINE study. Line graphs showing the mean (±SEM) PiB SUVR at baseline and at 12 months for 11 placebo (blue circles) and 16 PBT2 (red circles) participants in the IMAGINE double-blind phase of the study. In purple triangles, the 27 participants who completed the open label extension study. As comparison group, a group of 40 AIBL participants (black squares) meeting the IMAGINE inclusion criteria and matched for the baseline PiB SUVR of the 27 participants who completed the two phases of the IMAGINE study. While there were no significant differences between the 11 placebo and 16 PBT2 participants at 12 months, there was a significant decrease of 0.14 PiB SUVR/yr in the PBT2 group ( P = .005). While the 11 IMAGINE placebo participants showed a nonsignificant decrease of 0.07 PiB SUVR/yr, the AIBL participants showed a significant increase of 0.04 PiB SUVR/yr ( P = .0014). While no significant changes in PiB SUVR from 12 to 24 months were observed on the 27 participants who completed the IMAGINE open-label phase, a significant decrease of 0.04 PiB SUVR/yr ( P = .05) was observed when changes in PiB SUVR from 0 to 24 months were considered. Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; SUVR, standardized uptake volume ratio. ∗ P < .05; ∗∗P < .001.

Figure Legend Snippet: Longitudinal PiB SUVR data from participants who completed the two phases of the IMAGINE study. Line graphs showing the mean (±SEM) PiB SUVR at baseline and at 12 months for 11 placebo (blue circles) and 16 PBT2 (red circles) participants in the IMAGINE double-blind phase of the study. In purple triangles, the 27 participants who completed the open label extension study. As comparison group, a group of 40 AIBL participants (black squares) meeting the IMAGINE inclusion criteria and matched for the baseline PiB SUVR of the 27 participants who completed the two phases of the IMAGINE study. While there were no significant differences between the 11 placebo and 16 PBT2 participants at 12 months, there was a significant decrease of 0.14 PiB SUVR/yr in the PBT2 group ( P = .005). While the 11 IMAGINE placebo participants showed a nonsignificant decrease of 0.07 PiB SUVR/yr, the AIBL participants showed a significant increase of 0.04 PiB SUVR/yr ( P = .0014). While no significant changes in PiB SUVR from 12 to 24 months were observed on the 27 participants who completed the IMAGINE open-label phase, a significant decrease of 0.04 PiB SUVR/yr ( P = .05) was observed when changes in PiB SUVR from 0 to 24 months were considered. Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; SUVR, standardized uptake volume ratio. ∗ P < .05; ∗∗P < .001.

Techniques Used: Comparison, Imaging, Biomarker Discovery

Comparison of the IMAGINE study PiB results with the reported PiB results of the bapineuzumab trial , , and the florbetapir results from the aducanumab trial . To allow comparison between the different Aβ tracers, florbetapir SUVR WCb are expressed in PiB Cb -like units called BeCKeTs . A striking difference between the IMAGINE and the bapineuzumab and aducanumab trials is the Aβ burden at baseline. Overall, IMAGINE participants not only had significantly higher baseline Aβ burden, these baseline values were at levels for which we have demonstrated the rates of Aβ accumulation slow , making it difficult to discriminate between a potential drug effect that slows Aβ accumulation and the natural slowing that occurs at those SUVR levels. These comparisons highlight the importance of not only establishing a SUVR floor, but also the need of establishing a SUVR ceiling to ensure all participants are accumulating Aβ at a similar rate. Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; SUVR, standardized uptake volume ratio. ∗ P < .05; ∗∗ P < .001.

Figure Legend Snippet: Comparison of the IMAGINE study PiB results with the reported PiB results of the bapineuzumab trial , , and the florbetapir results from the aducanumab trial . To allow comparison between the different Aβ tracers, florbetapir SUVR WCb are expressed in PiB Cb -like units called BeCKeTs . A striking difference between the IMAGINE and the bapineuzumab and aducanumab trials is the Aβ burden at baseline. Overall, IMAGINE participants not only had significantly higher baseline Aβ burden, these baseline values were at levels for which we have demonstrated the rates of Aβ accumulation slow , making it difficult to discriminate between a potential drug effect that slows Aβ accumulation and the natural slowing that occurs at those SUVR levels. These comparisons highlight the importance of not only establishing a SUVR floor, but also the need of establishing a SUVR ceiling to ensure all participants are accumulating Aβ at a similar rate. Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; SUVR, standardized uptake volume ratio. ∗ P < .05; ∗∗ P < .001.

Techniques Used: Comparison, Imaging, Biomarker Discovery

Image Search Results

Journal: Alzheimer's & Dementia : Translational Research & Clinical Interventions

Article Title: A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study

doi: 10.1016/j.trci.2017.10.001

Figure Lengend Snippet: Longitudinal PiB SUVR data from the IMAGINE double-blind phase. Line graphs showing the mean (±SEM) PiB SUVR at baseline and at 12 months for the placebo (blue circles) and PBT2 (red circles) groups. As a contemporaneous control group, a group of 46 AIBL participants (black circles) meeting the IMAGINE inclusion criteria and matched for IMAGINE baseline PiB SUVR. While there were no significant differences between placebo and PBT2 at 12 months, there was a significant decrease of 0.09 PiB SUVR/yr in the PBT2 group ( P = .048). While the IMAGINE placebo group showed a nonsignificant decrease of 0.08 PiB SUVR/yr, the AIBL participants showed a significant increase of 0.04 PiB SUVR/yr ( P = .0014), and an even greater increase (0.07 PiB SUVR/yr) was observed in the APOE ε4 placebo group of the bapineuzumab trial . Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; SUVR, standardized uptake volume ratio. ∗∗ P < .001.

Article Snippet: Peak detection was carried out using the inbuilt BioRad ProteinChip Data Manager Biomarker Wizard, (Version 3.07.004).

Techniques: Control, Imaging, Biomarker Discovery

Journal: Alzheimer's & Dementia : Translational Research & Clinical Interventions

Article Title: A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study

doi: 10.1016/j.trci.2017.10.001

Figure Lengend Snippet: Longitudinal PiB SUVR data from participants who completed the two phases of the IMAGINE study. Line graphs showing the mean (±SEM) PiB SUVR at baseline and at 12 months for 11 placebo (blue circles) and 16 PBT2 (red circles) participants in the IMAGINE double-blind phase of the study. In purple triangles, the 27 participants who completed the open label extension study. As comparison group, a group of 40 AIBL participants (black squares) meeting the IMAGINE inclusion criteria and matched for the baseline PiB SUVR of the 27 participants who completed the two phases of the IMAGINE study. While there were no significant differences between the 11 placebo and 16 PBT2 participants at 12 months, there was a significant decrease of 0.14 PiB SUVR/yr in the PBT2 group ( P = .005). While the 11 IMAGINE placebo participants showed a nonsignificant decrease of 0.07 PiB SUVR/yr, the AIBL participants showed a significant increase of 0.04 PiB SUVR/yr ( P = .0014). While no significant changes in PiB SUVR from 12 to 24 months were observed on the 27 participants who completed the IMAGINE open-label phase, a significant decrease of 0.04 PiB SUVR/yr ( P = .05) was observed when changes in PiB SUVR from 0 to 24 months were considered. Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; SUVR, standardized uptake volume ratio. ∗ P < .05; ∗∗P < .001.

Article Snippet: Peak detection was carried out using the inbuilt BioRad ProteinChip Data Manager Biomarker Wizard, (Version 3.07.004).

Techniques: Comparison, Imaging, Biomarker Discovery

Journal: Alzheimer's & Dementia : Translational Research & Clinical Interventions

Article Title: A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study

doi: 10.1016/j.trci.2017.10.001

Figure Lengend Snippet: Comparison of the IMAGINE study PiB results with the reported PiB results of the bapineuzumab trial , , and the florbetapir results from the aducanumab trial . To allow comparison between the different Aβ tracers, florbetapir SUVR WCb are expressed in PiB Cb -like units called BeCKeTs . A striking difference between the IMAGINE and the bapineuzumab and aducanumab trials is the Aβ burden at baseline. Overall, IMAGINE participants not only had significantly higher baseline Aβ burden, these baseline values were at levels for which we have demonstrated the rates of Aβ accumulation slow , making it difficult to discriminate between a potential drug effect that slows Aβ accumulation and the natural slowing that occurs at those SUVR levels. These comparisons highlight the importance of not only establishing a SUVR floor, but also the need of establishing a SUVR ceiling to ensure all participants are accumulating Aβ at a similar rate. Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; SUVR, standardized uptake volume ratio. ∗ P < .05; ∗∗ P < .001.

Article Snippet: Peak detection was carried out using the inbuilt BioRad ProteinChip Data Manager Biomarker Wizard, (Version 3.07.004).

Techniques: Comparison, Imaging, Biomarker Discovery

Review

Structured Review

Images

1) Product Images from "A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study"

Similar Products

Image Search Results